Last reviewed · How we verify
Tafenoquine plus Artesunate-pyronaridine
This combination targets malaria parasites through two complementary mechanisms: tafenoquine eliminates dormant liver-stage parasites and gametocytes, while artesunate-pyronaridine rapidly kills blood-stage parasites.
This combination targets malaria parasites through two complementary mechanisms: tafenoquine eliminates dormant liver-stage parasites and gametocytes, while artesunate-pyronaridine rapidly kills blood-stage parasites. Used for Uncomplicated malaria caused by Plasmodium falciparum or Plasmodium vivax.
At a glance
| Generic name | Tafenoquine plus Artesunate-pyronaridine |
|---|---|
| Sponsor | Menzies School of Health Research |
| Drug class | Antimalarial combination |
| Target | Plasmodium falciparum and Plasmodium vivax (parasite species); mechanism involves multiple targets including mitochondrial function and heme detoxification |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tafenoquine is an 8-aminoquinoline that acts on hypnozoites (dormant forms) in the liver and prevents transmission by targeting gametocytes. Artesunate-pyronaridine is a fixed-dose artemisinin-based combination that rapidly reduces parasitemia by generating reactive oxygen species and disrupting parasite metabolism. Together, they provide both rapid symptom relief and prevention of relapse and transmission.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum or Plasmodium vivax
Common side effects
- Nausea
- Vomiting
- Headache
- Abdominal pain
- Diarrhea
Key clinical trials
- Tafenoquine and ACTs (TADORE- Plus) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: